Victory Capital Management Cashes Out 11210 Shares of Crinetics Pharmaceuticals,
February 4, 2023
Trending News ☀️
Crinetics Pharmaceuticals ($NASDAQ:CRNX), Inc. recently had 11210 of its shares sold by Victory Capital Management Inc. Crinetics Pharmaceuticals is a biopharmaceutical company that focuses on discovering, developing, and commercializing therapeutics for rare endocrine diseases and endocrine-related tumors. Crinetics Pharmaceuticals is focused on two primary areas of research and development: endocrinology and oncology. For endocrinology, the company is currently researching treatments for conditions such as Cushing’s Syndrome, Congenital Adrenal Hyperplasia, and Primary Aldosteronism. In oncology, Crinetics is researching treatments for tumors such as Carcinoid Syndrome, Neuroendocrine Tumors, and other rare endocrine-related tumors. The company has developed a series of compounds designed to treat rare endocrine diseases and endocrine-related tumors. These compounds are currently in the preclinical and clinical stages of development, with the potential to be approved by the FDA.
Crinetics Pharmaceuticals is also working on developing an oral formulation of its compounds to improve patient convenience and compliance. Crinetics Pharmaceuticals also has collaborations with several companies, including Bausch Health Companies Inc., AstraZeneca, Biogen Idec, and Janssen Pharmaceuticals. These collaborations have allowed the company to expand its research and development capabilities and increase its pipeline of products. The sale of 11210 shares of Crinetics Pharmaceuticals by Victory Capital Management Inc. highlights the company’s potential for success in the biopharmaceutical industry. With a focus on developing treatments for rare endocrine diseases and endocrine-related tumors, Crinetics Pharmaceuticals has the potential to become a leader in the field.
Share Price
On Friday, the stock of CRINETICS PHARMACEUTICALS opened at $20.0 and closed at $19.9, down by 1.0% from last closing price of 20.1. It is worth noting that Victory Capital Management Inc. is not the only one cashing out its shares in Crinetics Pharmaceuticals, Inc. Recently, other leading investors such as BlackRock Inc., Janus Henderson Group PLC and Northern Trust Corporation have also sold off their shares in Crinetics Pharmaceuticals, Inc. However, it is also possible that Victory Capital Management Inc. is simply rebalancing its portfolio and investing in other more profitable opportunities. Regardless of the reason behind Victory Capital Management Inc.’s decision to cash out its shares in Crinetics Pharmaceuticals, Inc., market analysts are keeping a close eye on the company’s stock performance over the coming weeks. If the stock continues to decline and other major investors follow suit, it could be a sign that investors are losing faith in the company’s future prospects. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Crinetics Pharmaceuticals. More…
| Total Revenues | Net Income | Net Margin |
| 5.11 | -149.72 | -2932.9% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Crinetics Pharmaceuticals. More…
| Operations | Investing | Financing |
| -102.9 | -312.63 | 285.7 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Crinetics Pharmaceuticals. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 384.88 | 33.51 | 6.53 |
Key Ratios Snapshot
Some of the financial key ratios for Crinetics Pharmaceuticals are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -23.7% | – | -2961.5% |
| FCF Margin | ROE | ROA |
| -2042.6% | -25.6% | -24.6% |
Analysis
CRINETICS PHARMACEUTICALS is a biopharmaceutical company that develops drugs for endocrine-related diseases. GoodWhale provides an analysis of the company’s fundamentals, with a Risk Rating that indicates it is a medium risk investment. This assessment is based on a number of factors relating to the financial and business aspects of the company. GoodWhale has identified two risk warnings in the balance sheet and cashflow statement, so those should be carefully evaluated before investing. Furthermore, investors should keep an eye on the company’s financial performance and any changes in the industry or regulatory environment that could affect its operations. Overall, CRINETICS PHARMACEUTICALS is considered a medium risk investment, but understanding all the risks involved is essential before deciding to invest in the company. GoodWhale provides an in-depth analysis of the company’s fundamentals, and investors should consider registering with the service to gain access to all the information. More…
Peers
Crinetics Pharmaceuticals Inc is currently facing stiff competition within the pharmaceutical industry. It is up against Organicell Regenerative Medicine Inc, Inhibikase Therapeutics Inc, and Belite Bio Inc, all of which are in the race to develop and market the most promising drugs. The competition between these companies is fierce and the stakes are high as they strive to be the first to make a breakthrough in their respective field of medicine.
– Organicell Regenerative Medicine Inc ($OTCPK:OCEL)
Organicell Regenerative Medicine Inc is a publicly traded biotechnology company focused on the development and commercialization of regenerative medicine treatments for a range of medical conditions. Its market cap of 31 million as of 2022 reflects the company’s strong financial performance and strong potential for growth. The company’s Return on Equity (ROE) of 92.4% shows that it has been able to efficiently manage its assets and generate returns for shareholders. The company has a robust pipeline of products and services and is well positioned to capitalize on the growing market for regenerative medicine treatments.
– Inhibikase Therapeutics Inc ($NASDAQ:IKT)
Inhibikase Therapeutics Inc is a biopharmaceutical company that focuses on developing therapies for neurological diseases, especially those related to Parkinson’s and Alzheimer’s. As of 2022, the company has a market cap of 11.6 million, indicating a small but growing presence in the industry. The company’s Return on Equity (ROE) of -43.05%, however, suggests that it has not been able to generate a significant return on investment for its shareholders. This could be due to a variety of factors such as high operating costs, low sales volume, or a lack of efficient management. Despite this, Inhibikase Therapeutics Inc has continued to grow, indicating potential for future success.
Summary
Investing in Crinetics Pharmaceuticals Inc. (CRIN) is a high risk, high reward proposition. The company has seen a recent cash out of 11210 shares by Victory Capital Management Inc., which could indicate a potential upside in the stock.
However, media coverage has been mostly positive at the time of writing, so investors may want to consider this as a potential investment opportunity. Analyzing the company’s financials, future projections, and competitive landscape can help investors determine if CRIN is a worthwhile investment.
Additionally, investors should be aware of the risks associated with investing in the biotechnology sector, including potential losses due to regulatory issues and changes in the industry.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
